Fig. 2.

Age at loss of ambulation^b for propensity-score matched patients from the STRIDE Registry and CINRG DNHS. Propensity-score model covariates include age at first symptoms, age at first corticosteroid use, duration of deflazacort use and duration of use of corticosteroids other than deflazacort. Censor dates for censored patients in the STRIDE Registry were derived from the last assessment date across treatment, physical examination, vital signs, 6-min walk distance, timed function tests, North Star Ambulatory Assessments, percentage of predicted FVC and upper limb function tests. ‘+’ indicates a censored observation. Corticosteroid duration is calculated from the date at which corticosteroid use was started to the date of loss of ambulation or the date of the last assessment. CINRG DNHS Cooperative International Neuromuscular Research Group Duchenne Natural History Study, NC not calculable, STRIDE Strategic Targeting of Registries and International Database of Excellence. ^aNumber of patients at risk of having the event (loss of ambulation). ^bLoss of ambulation was defined as full-time wheelchair use. ^cp value is from a log-rank test stratified by deflazacort and other corticosteroid usage durations. ^dHazard ratio is from stratified (by durations of deflazacort and other corticosteroid use), Cox regression with study, age at first symptoms and age at first corticosteroid use as covariates. The hazard ratio is STRIDE Registry versus CINRG DNHS